The Signatera Test for Patients Previously Diagnosed with Cancer

Published on 16 Aug 2022
Last Updated on 16 Aug 2022

This Horizon Scanning Brief provides an assessment of the Signatera test to detect molecular residual disease in patients previously diagnosed with cancer.

The Signatera Test for Patients Previously Diagnosed with Cancer [PDF, 1.3 MB]